JP2022546040A5 - - Google Patents

Info

Publication number
JP2022546040A5
JP2022546040A5 JP2022513127A JP2022513127A JP2022546040A5 JP 2022546040 A5 JP2022546040 A5 JP 2022546040A5 JP 2022513127 A JP2022513127 A JP 2022513127A JP 2022513127 A JP2022513127 A JP 2022513127A JP 2022546040 A5 JP2022546040 A5 JP 2022546040A5
Authority
JP
Japan
Application number
JP2022513127A
Other languages
Japanese (ja)
Other versions
JP2022546040A (ja
JPWO2021037972A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2020/073961 external-priority patent/WO2021037972A1/en
Publication of JP2022546040A publication Critical patent/JP2022546040A/ja
Publication of JP2022546040A5 publication Critical patent/JP2022546040A5/ja
Publication of JPWO2021037972A5 publication Critical patent/JPWO2021037972A5/ja
Priority to JP2024180454A priority Critical patent/JP2025013845A/ja
Pending legal-status Critical Current

Links

JP2022513127A 2019-08-27 2020-08-27 Pcsk9を阻害するための組成物および方法 Pending JP2022546040A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024180454A JP2025013845A (ja) 2019-08-27 2024-10-16 Pcsk9を阻害するための組成物および方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19306036.5 2019-08-27
EP19306036 2019-08-27
PCT/EP2020/073961 WO2021037972A1 (en) 2019-08-27 2020-08-27 Compositions and methods for inhibiting pcsk9

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024180454A Division JP2025013845A (ja) 2019-08-27 2024-10-16 Pcsk9を阻害するための組成物および方法

Publications (3)

Publication Number Publication Date
JP2022546040A JP2022546040A (ja) 2022-11-02
JP2022546040A5 true JP2022546040A5 (https=) 2023-09-04
JPWO2021037972A5 JPWO2021037972A5 (https=) 2023-09-04

Family

ID=67956661

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022513127A Pending JP2022546040A (ja) 2019-08-27 2020-08-27 Pcsk9を阻害するための組成物および方法
JP2024180454A Pending JP2025013845A (ja) 2019-08-27 2024-10-16 Pcsk9を阻害するための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024180454A Pending JP2025013845A (ja) 2019-08-27 2024-10-16 Pcsk9を阻害するための組成物および方法

Country Status (5)

Country Link
US (1) US20220290156A1 (https=)
EP (1) EP4022061A1 (https=)
JP (2) JP2022546040A (https=)
CN (1) CN115176011B (https=)
WO (1) WO2021037972A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019006455A1 (en) 2017-06-30 2019-01-03 Solstice Biologics, Ltd. AUXILIARIES OF CHIRAL PHOSPHORAMIDITIS AND METHODS OF USE THEREOF
EP3884051A2 (en) 2018-11-23 2021-09-29 Sanofi Novel rna compositions and methods for inhibiting angptl8
JP7667775B2 (ja) * 2019-09-05 2025-04-23 サノフイ ヌクレオチド類似体を含有するオリゴヌクレオチド
WO2024002006A1 (zh) * 2022-06-27 2024-01-04 大睿生物医药科技(上海)有限公司 具有增强的稳定性的核苷酸替代物
JP2025532985A (ja) 2022-09-30 2025-10-03 アルナイラム ファーマシューティカルズ, インコーポレイテッド 修飾二本鎖rna剤
WO2024228030A2 (en) * 2023-05-04 2024-11-07 Argonaute RNA Limited Dual silencing
CN121866332A (zh) * 2023-06-21 2026-04-14 美国圣因生物股份有限公司 靶向前蛋白转化酶枯草杆菌蛋白酶kexin 9(pcsk9)的双链rna及其使用方法
WO2025077949A1 (zh) * 2023-11-06 2025-04-17 杭州天龙药业有限公司 提升双链寡核苷酸靶基因抑制效果的修饰模板及其组合与应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5665710A (en) 1990-04-30 1997-09-09 Georgetown University Method of making liposomal oligodeoxynucleotide compositions
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
US5587308A (en) 1992-06-02 1996-12-24 The United States Of America As Represented By The Department Of Health & Human Services Modified adeno-associated virus vector capable of expression from a novel promoter
WO1994002595A1 (en) 1992-07-17 1994-02-03 Ribozyme Pharmaceuticals, Inc. Method and reagent for treatment of animal diseases
US5478745A (en) 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
US6054299A (en) 1994-04-29 2000-04-25 Conrad; Charles A. Stem-loop cloning vector and method
US5981501A (en) 1995-06-07 1999-11-09 Inex Pharmaceuticals Corp. Methods for encapsulating plasmids in lipid bilayers
ATE285477T1 (de) 1995-06-07 2005-01-15 Inex Pharmaceutical Corp Herstellung von lipid-nukleinsäure partikeln duch ein hydrophobische lipid-nukleinsäuree komplexe zwischenprodukt und zur verwendung in der gentransfer
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
NZ507093A (en) 1998-04-08 2003-08-29 Commw Scient Ind Res Org Methods and means for reducing the phenotypic expression of a nucleic acid of interest in a plant
AR020078A1 (es) 1998-05-26 2002-04-10 Syngenta Participations Ag Metodo para alterar la expresion de un gen objetivo en una celula de planta
WO2000003683A2 (en) 1998-07-20 2000-01-27 Inex Pharmaceuticals Corporation Liposomal encapsulated nucleic acid-complexes
BR9914773A (pt) 1998-10-09 2002-02-05 Ingene Inc Conjunto de elementos genéricos, método para a produção de dna de cordão único, transcrição de mrna, construção de ácido nucléico, transcrição de ssdna, vetor, sistema vetor, célula hospedeira, conjunto para a produção de uma sequência de ácido nucléico de cordão único, método para a produção in vivo ou in vitro de uma sequência de ácido nucléico de cordão único, transcrição de cdna de cordão único, ácido nucléico inibidor, molécula heteroduplex, e composição farmacêutica
MXPA01003642A (es) 1998-10-09 2003-07-21 Ingene Inc Sintesis enzimatica de adnss.
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
CN100365122C (zh) * 2005-12-30 2008-01-30 中国疾病预防控制中心病毒病预防控制所 针对乙型流感病毒多聚酶基因的siRNA序列及其应用
ES2874149T3 (es) * 2006-05-11 2021-11-04 Alnylam Pharmaceuticals Inc Composiciones y métodos para inhibir la expresión del gen PCSK9
AU2007275365A1 (en) * 2006-07-17 2008-01-24 Sirna Therapeutics Inc. RNA interference mediated inhibition of Proprotein Convertase Subtilisin Kexin 9 (PCSK9) gene expression using short interfering nucleic acid (siNA)
WO2009082607A2 (en) 2007-12-04 2009-07-02 Alnylam Pharmaceuticals, Inc. Targeting lipids
US20100249214A1 (en) 2009-02-11 2010-09-30 Dicerna Pharmaceuticals Multiplex dicer substrate rna interference molecules having joining sequences
NZ597504A (en) * 2009-06-15 2013-10-25 Alnylam Pharmaceuticals Inc Lipid formulated dsrna targeting the pcsk9 gene
WO2013154766A1 (en) * 2012-04-13 2013-10-17 New York University Microrna control of ldl receptor pathway
US10125369B2 (en) * 2012-12-05 2018-11-13 Alnylam Pharmaceuticals, Inc. PCSK9 iRNA compositions and methods of use thereof
DK2991656T3 (da) 2013-05-01 2020-03-23 Ionis Pharmaceuticals Inc Sammensætninger og fremgangsmåder til modulering af apolipoprotein c-iii-ekspression
EP3762395A1 (en) * 2018-03-07 2021-01-13 Sanofi Nucleotide precursors, nucleotide analogs and oligomeric compounds containing the same
US11566248B2 (en) * 2018-04-18 2023-01-31 Dicerna Pharmaceuticals, Inc. PCSK9 targeting oligonucleotides for treating hypercholesterolemia and related conditions

Similar Documents

Publication Publication Date Title
JP2022546040A5 (https=)
CL2025003474A1 (es) Sales agonistas de sstr4.
BR202021015276U2 (https=)
CN305535721S (https=)
CN305535716S (https=)
CN305535706S (https=)
CN305533789S (https=)
CN305533590S (https=)
CN305533049S (https=)
CN305531786S (https=)
CN305531460S (https=)
CN305530651S (https=)
CN305530366S (https=)
CN305529440S (https=)
CN305528864S (https=)
CN305527925S (https=)
CN305527538S (https=)
CN305527207S (https=)
CN305527033S (https=)
CN306580102S (https=)
CN306161657S (https=)
CN306161256S (https=)
CN306160603S (https=)
CN306150609S (https=)
CN306148494S (https=)